

---

---

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT  
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) **May 30, 2013**

**OCULUS INNOVATIVE SCIENCES, INC.**  
(Exact name of registrant as specified in its charter)

**Delaware**  
(State or other jurisdiction  
of incorporation)

**001-33216**  
(Commission  
File Number)

**68-0423298**  
(IRS Employer  
Identification No.)

**1129 N. McDowell Blvd, Petaluma, CA**  
(Address of principal executive offices)

**94954**  
(Zip Code)

**(707) 283-0550**  
(Registrant's telephone number, including area code)

**Not applicable.**  
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- £ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- £ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- £ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- £ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
- 
-

**Item 7.01 Regulation FD Disclosure.**

Oculus Innovative Sciences, Inc. is participating in the Marcum MicroCap Conference on Thursday, May 30, 2013. Jim Schutz, President and Chief Executive Officer of Oculus, is scheduled to deliver a presentation beginning at 1:30pm EDT at the conference. The presentation slides for use in conjunction with the conference are being furnished pursuant to Regulation FD as Exhibit 99.1 to this Current Report on Form 8-K.

A copy of the slide presentation for use in connection with the conference is attached to this Current Report on Form 8-K as Exhibit 99.1, and incorporated by reference herein. The slide presentation contained in the exhibit includes statements intended as "forward-looking statements," which are subject to the cautionary statement about forward-looking statements set forth in the exhibit. The slide presentation is being furnished, not filed, pursuant to Regulation FD. Accordingly, the slide presentation will not be incorporated by reference into any registration statement filed by the Company under the Securities Act of 1933, as amended, unless specifically identified therein as being incorporated therein by reference. The furnishing of the slide presentation is not intended to, and does not, constitute a determination or admission by the Company that the information in the slide presentation is material or complete, or that investors should consider this information before making an investment decision with respect to any security of the Company.

**Item 9.01 Financial Statements and Exhibits.**

Exhibits

99.1 Slide Presentation dated May 30, 2013.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Oculus Innovative Sciences, Inc.  
(Registrant)

Date: May 30, 2013

By: /s/ Robert Miller

Name: Robert Miller

Title: Chief Financial Officer



  
**OCULUS**  
Innovative Sciences



## **The Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995**

This presentation includes forward-looking statements that are made pursuant to the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. While these statements are made to convey to the public the company’s progress, business opportunities and growth prospects, readers and listeners are cautioned that such forward-looking statements represent management’s opinion. Whereas management believes such representation to be true and accurate, based on information and data available to the Company at this time, actual results may differ materially from those described. The company’s operations and business prospects are always subject to risk and uncertainties. Important factors that may cause actual results to differ are set forth in the Company’s periodic filings with the U.S. Securities and Exchange Commission.


**Nasdaq: OCLS**



# Era of Antibiotics - Penicillin



**Fleming  
1928**



**Florey  
& Chain  
1940**


  
**OCULUS**  
Innovative Sciences

**“The time has come to close the book on infectious diseases. We have basically wiped out infection in the United States.”**

William Stewart, U.S. Surgeon General, 1967



# Antibiotics: Dates of Discovery




# U.S. Antimicrobial Use

## U.S. Antimicrobial Use



**OCULUS**  
Innovative Sciences





**“The danger posed by growing resistance to antibiotics should be ranked along with terrorism on a list of threats to the nation.”**

**UK's Chief Medical Officer,  
Professor Dame Sally Davies  
Mar 2013**

  
**OCULUS**  
Innovative Sciences



## **Studying Microbes in Frozen Tundra**


  
**OCULUS**  
Innovative Sciences

# Human Immune System



  
**OCULUS**  
Innovative Sciences

# Neutrophil Mode of Action



# The Breakthrough – Non-Antibiotic Antimicrobial

Kills broad spectrum of:

- bacteria, viruses, spores and fungi
- antibiotic-resistant strains (MRSA, VRE)



Due to a different MOA,  
**no facilitation of pathogenic resistance**

**4 million patients** without any significant adverse events

Proven efficacy in over 30 studies, including randomized/controlled Phase II FDA study against levofloxacin

# Dr. Adam Landsman

“Microcyn is one of the few topicals that’s effective for patients that are affected with **MRSA** ...”



Assistant Professor  
Harvard Medical School



# Dr. Tom Wolvos

“Microcyn seems to decrease inflammation ... I changed to Microcyn gel and saw not only healing of the wound, but a **dramatic decrease in the inflammatory reaction** that my patient experienced when treated with an antibiotic ointment.”



Chief of General Surgery  
Scottsdale Healthcare  
Scottsdale, Arizona

Editor of the *Scottsdale  
Wound Management Guide*

**OCULUS**  
Innovative Sciences

# Acute Care/Hospital Products



**U.S. Partner: Eloquest Healthcare® is focused specifically on serving hospitals, their healthcare practitioners, and patients. Eloquest Healthcare® provides value within the acute care market by helping to improve patient outcomes.**

  
**OCULUS**  
Innovative Sciences



# Dermatology Products



**U.S. Partner: Quinnova Pharmaceuticals is a specialty pharmaceutical company founded on innovative, patent-protected dermal delivery technologies**



# Dr. Rebecca Smith

“I see a lot of colonization of MRSA. I see kids with chronic atopic dermatitis who end up with the infection over again and again and again. And they’re often colonized in their nose, **so I can take the solution or the gel even and have them apply in their noses a couple of times a day.** This cuts down on the colonization so I can prevent chronic recurrence of superficial MRSA.”



Dermatologist  
Fort Mill Dermatology  
South Carolina

  
**OCULUS**  
Innovative Sciences

# Animal Healthcare Products



**Partner:** Innovacyn Inc. is a privately held company that provides premier human and animal healthcare products based on advanced scientific research



# Cesar Millan

“Vetericyn will help your dog heal faster from a wound or infection. That means fewer costly and stressful visits to the vet.”

“Vetericyn is great to use on **hot spots, rashes and skin irritations**. It is safe as water and contains no steroids, antibiotics, alcohol or other harmful ingredients.”



The Dog Whisperer

  
**OCULUS**  
Innovative Sciences



# Summary Income Statement

	Three Months Ended		Nine Months Ended	
	December 31,		December 31,	
	2012	2011	2012	2011
<b>Revenues</b>				
Product	\$ 3,357	\$ 2,597	\$11,437	\$ 8,697
Service	183	193	680	696
<b>Total revenues</b>	<b>3,540</b>	<b>2,790</b>	<b>12,117</b>	<b>9,393</b>
<b>Cost of revenues</b>				
Product	906	757	2,986	2,215
Service	163	181	576	599
<b>Total cost of revenues</b>	<b>1,069</b>	<b>938</b>	<b>3,562</b>	<b>2,814</b>
<b>Gross profit</b>	<b>2,471</b>	<b>1,852</b>	<b>8,555</b>	<b>6,579</b>
<b>Operating expenses</b>				
Research and developmen	509	509	1,554	1,505
Selling, general and admini	2,642	3,697	8,993	10,076
<b>Total operating expenses</b>	<b>3,151</b>	<b>4,206</b>	<b>10,547</b>	<b>11,581</b>
<b>Loss from operations</b>	<b>(680)</b>	<b>(2,354)</b>	<b>(1,992)</b>	<b>(5,002)</b>
<b>Other expense, net</b>	<b>(1,232)</b>	<b>(193)</b>	<b>(994)</b>	<b>(559)</b>
<b>Net loss</b>	<b>(1,912)</b>	<b>(2,547)</b>	<b>(2,986)</b>	<b>(5,561)</b>



# Breakeven Analysis

	Q3	Break	Product Revenue Growth**		
	FY2013	Even	10%	20%	40%
Product revenue*	\$3.36	\$3.30	\$3.63	\$3.96	\$4.62
Service revenue	\$0.18	\$0.20	\$0.20	\$0.20	\$0.20
Total revenue	\$3.54	\$3.50	\$3.83	\$4.16	\$4.82
Gross margins (cash)	\$2.41	\$2.35	\$2.58	\$2.81	\$3.27
Product margins	73%	70%	70%	70%	70%
Cash operating expenses**	\$2.70	\$2.35	\$2.40	\$2.50	\$2.60
EBITDAS	-\$0.29	\$0.00	\$0.18	\$0.31	\$0.67
% of sales			5%	7%	14%

\*Dollars in million

\*\* Breakeven and growth is after separation of Ruthigen and without their expenses



# Current Revenue Sources

Partners	Approvals	SKUs	Commercialized	Markets
Innovacyn	FDA 510K	40+	2009	US/Int'l: Animal health
AmDerma	FDA 510K	3	2012	US: Derm Rx
Eloquest	FDA 510K	7	2012	US: Acute care
More Pharma	MOH Drug	4	2005	Mexico: Pharmacy, hospital, dermatology
Alkem	Drug	3		India: Hospital and pharmacy
Shanghai Sunvic	Device	3	2013	China: Hospital and pharmacy
EU Distributors	Device	2	2005	EU: Acute care



# Key Facts

Closing Stock Price 52-week Range	\$2.66-\$8.47
Shares Outstanding	5.3M
Options/Warrants Outstanding	2.5M
Market Capitalization	\$20.7M
Average Daily Volume (52 week)	12,000
Trailing Revenue (12 months ending 12/31/12)	\$15.5M
Net Loss minus non-cash expenses (3 months ending 12/31/12)	\$289K
Insider Ownership	4%
Full-Time Employees	43

All data as of 12/31/12. All share and per share data reflects 1 for 7 reverse split



# Intellectual Property

## 35 Issued Patents

- 5 issued US
- 12 issued EU
- 18 issued International

## Pending Applications

- 109 U.S. and foreign

## Claims Covering:

- Chemical composition
- Apparatus
- Method of manufacturing
- Therapeutic uses

IP ruled enforceable by U.S.  
Federal Court in 2009



# Preliminary Scar Data

## Investigator Global Assessment:

**% Very good/ good at Day 84**

<u>Microcyn</u>	<u>Market Leader</u>
55%	38%

## % Improvement of Microcyn over Market Leader: (based on % reduction from base line)

	Day 84		<u>Difference</u>	Percentage	
	<u>Microcyn</u>	<u>Leader</u>		<u>Improvement</u>	<u>P values</u>
Vascularity	-42%	-28%	-14%	50%	25%
Pliability	-47%	-34%	-13%	38%	22%
Height	-30%	-11%	-19%	173%	7%
Vancouver	-40%	-26%	-14%	55%	8%
Pain	-100%	-72%	-28%	39%	12%
Itch	-78%	-70%	-8%	11%	65%

# “De-Risked Company”

Microcyn Technology marketed in **more than 20 countries**

Last three years => average revenue growth = **35%**

Robust product pipeline in US, Europe, Mexico/Latin America, Middle East and Asia

Expanding global footprint

**Ruthigen** => internally used antimicrobial drug focused on prevention of surgically acquired infections



# More Information

**Jim Schutz, Oculus CEO**

[jschutz@oculusis.com](mailto:jschutz@oculusis.com)

**Bob Miller, Oculus CFO**

[bmiller@oculusis.com](mailto:bmiller@oculusis.com)

**Dan McFadden, Oculus VP of IR/PR**

[dmcfadden@oculusis.com](mailto:dmcfadden@oculusis.com)

**Oculus Innovative Sciences** 1129 North McDowell  
Blvd. Petaluma, California 94954 Telephone: +1 (707)  
283-0550

[www.oculusis.com](http://www.oculusis.com)

**Nasdaq: OCLS**

